Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Merck

Last Updated: May 26, 2022

Investigational Drug Information for MK-3682


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug MK-3682?

MK-3682 is an investigational drug.

There have been 8 clinical trials for MK-3682. The most recent clinical trial was a Phase 2 trial, which was initiated on December 10th 2015.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].

There are six US patents protecting this investigational drug and one hundred and twenty-two international patents.

Recent Clinical Trials for MK-3682
TitleSponsorPhase
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)Merck Sharp & Dohme Corp.Phase 2
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)Merck Sharp & Dohme Corp.Phase 2
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)Merck Sharp & Dohme Corp.Phase 1

See all MK-3682 clinical trials

Clinical Trial Summary for MK-3682

Top disease conditions for MK-3682
Top clinical trial sponsors for MK-3682

See all MK-3682 clinical trials

US Patents for MK-3682

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MK-3682 See Plans and Pricing Process for making chloro-substituted nucleoside phosphoramidate compounds Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
MK-3682 See Plans and Pricing Process for making nucleoside phosphoramidate compounds Merck Sharp & Dohme Corp. (Rahway, NJ) Idenix Pharmaceuticals LLC (Cambridge, MA) See Plans and Pricing
MK-3682 See Plans and Pricing 2'-chloro nucleoside analogs for HCV infection IDENIX PHARMACEUTICALS LLC (Cambridge, MA) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MK-3682

Drugname Country Document Number Estimated Expiration Related US Patent
MK-3682 World Intellectual Property Organization (WIPO) WO2016064797 2034-10-20 See Plans and Pricing
MK-3682 African Regional IP Organization (ARIPO) AP3913 2032-05-22 See Plans and Pricing
MK-3682 Argentina AR092835 2032-05-22 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.